Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.80 USD
Change Today -0.003 / -0.37%
Volume 70.1K
DARA On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

dara biosciences inc (DARA) Key Developments

DARA BioSciences, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

DARA BioSciences Inc. announced earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net revenues of $717,800 against $53,600 a year ago. Net loss attributed to controlling interest was $1,649,500 against $2,354,100 a year ago. The company reported a loss of $0.04 per share. For the year, the company reported net revenues of $1.89 million based on gross product sales of $2.32 million, as compared to net revenues of $419,000 for the year ended December 31, 2013, a year over year increase of 350%. The increase in Revenue was primarily attributable to the expanded commercial sales organization and success in generating interest and prescriptions across DARA's portfolio. The company reported a loss attributable to controlling interest of approximately $9.00 million or $0.63 per share as compared to a loss attributable to controlling interest of approximately $9.97 million, or $1.94 per share for the full year ended December 31, 2013. The loss attributable to controlling interest for the year was $963,887 less than the same period last year.

DARA BioSciences, Inc to Report Q4, 2014 Results on Mar 03, 2015

DARA BioSciences, Inc announced that they will report Q4, 2014 results After-Market on Mar 03, 2015

DARA BioSciences, Inc, Q4 2014 Earnings Call, Mar 04, 2015

DARA BioSciences, Inc, Q4 2014 Earnings Call, Mar 04, 2015

DARA BioSciences, Inc Presents at 27th Annual ROTH Conference, Mar-10-2015 04:00 PM

DARA BioSciences, Inc Presents at 27th Annual ROTH Conference, Mar-10-2015 04:00 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Christopher G. Clement, Chief Executive Officer, President and Director.

Dara Biosciences Receives Waiver of Approximately $1.1 Million for Product and Establishment Fees by the FDA

DARA BioSciences Inc. announced that it has been granted a barrier-to-innovation waiver for certain product and establishment fees. The Food and Drug Administration has granted company's request for a barrier-to-innovation waiver of the fiscal year 2012 product and establishment fees, fiscal year 2013 product fee, and fiscal year 2014 product and establishment fees for NDA, 21-807, Soltamox oral solution totaling approximately $1.1 million. A waiver or reduction in PDUFA fees may be appropriate when the product for which the waiver is being requested is innovative or the entity requesting the waiver is otherwise pursuing innovative drug products or technology, and the fee would be a significant barrier to the entity's ability to develop, manufacture, or market innovative products or technology. Specifically, the FDA acknowledged company's development work surrounding its KRN5500 asset during the years relating to the waiver, and determined that the imposition of the fees during those years created a significant financial barrier to the company. The company has requested a similar waiver for 2015. The FDA's Office of Financial Management (OFM) has been directed to refund the fees related to fiscal year 2012 already remitted by the company in the amount of approximately $619,000 which should be processed and refunded within 30 days from the waiver being granted. The fees related to fiscal years 2013 and 2014 which have not been remitted total approximately $480,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DARA:US $0.80 USD -0.003

DARA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
PlasmaTech Biopharmaceuticals Inc $2.83 USD +0.02
View Industry Companies
 

Industry Analysis

DARA

Industry Average

Valuation DARA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.3x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DARA BIOSCIENCES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.